Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771868 | 0.92 | TRPA1 (0.41) | PDE4APDE4BPDE4CPDE4DADORA2B | |
| SCHEMBL5790131 | 0.88 | TRPA1 (0.38) | PDE4APDE4BPDE4CPDE4DADORA2B | |
| SCHEMBL13217673 | 0.86 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DADORA2B | |
| SCHEMBL6383651 | 0.85 | KMT2A (0.37) | PDE4APDE4BPDE4CPDE4DADORA2B | |
| SCHEMBL6383655 | 0.84 | PDE4A (0.35) | PDE4APDE4BPDE4CPDE4DADORA2B | |
| SCHEMBL6380593 | 0.83 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DADORA2B | |
| SCHEMBL2967449 | 0.82 | PDE1A (0.62) | ADORA2BSMN1; SMN2 | |
| SCHEMBL13652738 | 0.79 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2B | |
| SCHEMBL11380715 | 0.79 | PDE1A (0.57) | PDE4APDE4BPDE4CPDE4DADORA2B | |
| SCHEMBL11375296 | 0.79 | ADORA2B (0.62) | ADORA2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | EISAI CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20060100199-A1 | Novel condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060063787-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1557165-A1 | COMBINATION DRUG | Eisai Co., Ltd. (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1514552-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | Eisai Co., Ltd. (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20040116328-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | MYT1, AQP4, AQP1 | PDE4A 3211/4885PDE4B 3705/4885PDE4C 4007/4885 |
| US-20060100199-A1 | Novel condensed imidazole derivatives | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4 | PDE4A 4058/4885PDE4B 3679/4885PDE4C 4206/4885 |
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | PDE4A 39/4885PDE4B 38/4885PDE4C 68/4885 |
| US-20060063787-A1 | Condensed imidazole derivatives | DPP4, HDAC1, DPP7 | PDE4A 1635/4885PDE4B 996/4885PDE4C 2472/4885 |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | PDE4A 1635/4885PDE4B 996/4885PDE4C 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.